ecancermedicalscience

Research

Comparison analysis of serum interleukin-6 levels and cervical cancer

7 Oct 2025
Muisi A Adenekan, Joseph B Minari, Ayodeji Adefemi, Gbenga Olorunfemi, Ayomide I Fayinto, Adebayo Sekumade, Temitope V Adekanye, Adeyemi A Okunowo, Kehinde S Okunade

Synopsis: We found a significant increase in serum IL-6 levels of 214.9 ng/mL (95% CI: 60.1–369.7, p = 0.007) among women with cervical cancer (CC) compared to their cancer-free counterparts.

Objectives: Despite growing evidence of the role of interleukin-6 (IL-6) in CC, studies assessing this association among women of sub-Saharan African origin remain limited. This study investigated the association between serum IL-6 and CC and explored the effects of serum IL-6 levels on prognosis in patients with CC in Lagos, Nigeria.

Methods: We conducted a cross-sectional study among women with and without CC in two hospitals. A venous blood sample was collected from each participant for laboratory analysis of serum IL-6 levels. We performed simple and multiple linear regression analyses to compare the unit increase in serum IL-6 levels between study groups while adjusting for relevant confounders.

Results: Our study found a significant unit increase of 214.9 ng/mL (95%CI: 60.1–369.7, p = 0.007) in serum IL-6 levels among women with CC compared to their cancer-free counterparts. The area under the curve of 0.814 demonstrated a good discriminatory ability at an optimal serum IL-6 cut-off value of 365.1 ng/mL. IL-6 levels were significantly elevated in patients with advanced-stage CC compared to those with early-stage disease (156.7 (IQR: 130.4–227.6) versus 324.7 (IQR: 188.5–516.2) ng/mL) and in patients diagnosed with squamous cells carcinoma (SCC) compared to those without SCC (523.9 (IQR: 365.1–682.1) versus 203.6 (IQR: 131.3–334.3) ng/mL).

Conclusion: Our study findings highlight the potential utility of serum IL-6 as a biomarker for CC diagnosis and prognosis. However, further studies are needed to explore the utility of IL-6 as a target for therapeutic intervention and in the treatment monitoring of CC patients.

Artículos relacionados

José Fernando Robles Díaz, Adela Heredia Zelaya, Alicia Milagros Avalos Rosas
María Eugenia Giavedoni, Lucas Staringer, Rosa Garrido, Cintia Bertoncini, Mabel Sardi, Myriam Perrotta
Estefania Moreno-Luna, Patricia Alonso, Javier De Santiago, Ignacio Zapardiel